You are here: Industry Insights > Alzheimer's Disease

News List

Neurotrope Announces First Patient Dosed in Bryostatin Trial for Alzheimer's Disease americanpharmaceuticalreview
October 12, 2020
Neurotrope has announced the dosing of the first patient in its ongoing, long-term Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease (AD).
Biogen Submits BLA for Aducanumab in Alzheimer's Disease contractpharma
July 10, 2020
If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer's disease.
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn for Alzheimer's Disease americanpharmaceuticalreview
July 03, 2020
BrainStorm Cell Therapeutics announced a new clinical program focused on the development of NurOwn® as a treatment for Alzheimer's disease.
Lilly Receives FDA Approval of TAUVID for Patients Being Evaluated for Alzheimer's Disease americanpharmaceuticalreview
June 09, 2020
TAUVID™ has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment ...
Neurotrope, NIH Launch Clinical Trial of Bryostatin for Alzheimer's Disease americanpharmaceuticalreview
June 08, 2020
Neurotrope announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD).
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 25, 2019
Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 24, 2019
Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
Denovo Biopharma Receives Global Rights to Novel Late-Stage Drug for Alzheimer's Disease americanpharmaceuticalreview
June 21, 2019
Denovo Biopharma has licensed ORM-12741 from Orion Corporation. Denovo gains global rights to develop, manufacture and commercialize ORM-12741.
Even Distant Relatives' History Could Up Your Alzheimer's Risk drugs
March 14, 2019
A grandparent's mental decline or a great uncle's waning memory may indicate you, too, have greater risk for Alzheimer's disease -- especially if closer relatives have the condition, a new study says.
Following deal focused on Alzheimer's disease, AbbVie, Voyager Therapeutics expand collaboration to Parkinson's disease firstwordpharma
February 23, 2019
AbbVie entered an exclusive global agreement with Voyager Therapeutics to develop vectorised antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases characterised by the abnormal

Previous page 1 2 3 4 Next page